Liquidia (NASDAQ:LQDA) Bolsa

LIQUIDIA CORP

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Macro Economic Events

News

Economics

Bessent Says I Think We Could Have Trade Wrapped Up By Labor Day

The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Enflonsia (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">their first RSV season</a>.
With a <a target="_blank" href="https://www.cdc.gov/media/releases/2025/2025-cdcs-advisory-committee-on-immunization-concludes-meeting-with-joint-statement.html" rel="noreferrer noopener">five-to-two </a>majority, RFK&#8217;s newly constituted committee made its first ruling. This body was formed after RFK entirely replaced the previous 17-member panel with his own selections.
The ACIP also voted to include Enflonsia in the Vaccines for Children Program, an essential step in ensuring broad access to this preventive <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46122920/acip-recommends-use-of-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-v" rel="noreferrer noopener">option for infants</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/06/46109624/rfk-jr-overhauls-cdc-vaccine-panel-sparking-expert-backlash-boycott-from-top-medical-group" rel="noreferrer noopener">RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group</a>
Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid, and durable protection through 5 months, a typical RSV season, with the same dose regardless of weight.
A typical RSV season usually spans autumn to spring of the next year. The U.S. Food and Drug Administration (FDA) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45846612/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-r" rel="noreferrer noopener">approved Enflonsia in June</a>.
The approval is based on results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of Enflonsia administered to preterm and full-term infants (birth to 1 year of age). The trial met its primary and key secondary endpoints.
Enflonsia demonstrated a reduction in incidence of RSV-associated medically attended lower respiratory infections (MALRI) requiring ≥1 indicator of lower respiratory infection (LRI) or severity compared to placebo through 5 months (primary endpoint) by 60.5% (incidence rates: Enflonsia, 0.026; placebo, 0.065).
Enflonsia demonstrated a reduction in RSV-associated hospitalizations through 5 months (key secondary endpoint) by 84.3% (incidence rates: Enflonsia, 0.004; placebo, 0.024), showing increasing efficacy with increasing disease severity.
Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.
The ACIP&#8217;s recommendation for Enflonsia is provisional and will become official once it is reviewed and finalized by the CDC Director or the Health and Human Services Secretary (in the absence of a CDC Director).
Price Action: MRK stock is up 0.33% at $79.10 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

General

RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants

HC Wainwright &amp; Co. analyst Sean Lee maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and lowers the price target from $5.5 to $3.

Price Target

Analyst Ratings

PSTV

HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $3

TSBX

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

As market volatility intensifies and economic uncertainty remains persistent, investors increasingly see holding companies in the marketing technology (MarTech) and public relations (PR) sectors as attractive investment opportunities. The recent wave of consolidation within these industries not only streamlines operational efficiency but also sets the stage for significant growth as market conditions stabilize and businesses seek comprehensive, integrated, and scalable solutions.
Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>), often referred to by industry insiders as the "Goldilocks Network," exemplifies the strategic advantages of sector consolidation. Stagwell maintains a balanced portfolio that combines the agility and innovation typical of smaller agencies with the extensive resources and capabilities of a larger network. Under the leadership of CEO Mark Penn, who previously advised President Clinton and served as Microsoft&#8217;s Chief Strategy Officer, Stagwell has proactively leveraged consolidation trends to enhance its expertise in digital transformation, advanced analytics, communication strategies, and performance marketing. The firm is strategically positioned to reach nearly $5 billion in annual revenue by 2029, reflecting the tangible benefits consolidation can yield in terms of market competitiveness and shareholder value.
Similarly, Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>), a global powerhouse in marketing communications and advertising, continues to capitalize on industry consolidation by integrating specialized agencies into its vast network. Omnicom's robust balance sheet and extensive global presence enable rapid integration of innovative services, technologies, and expertise. By continuously broadening its offerings in data-driven marketing, branding, crisis communications, and digital media analytics, Omnicom remains resilient, adaptive, and well-equipped to respond swiftly to evolving market dynamics, presenting investors with a stable growth trajectory.
Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) has also adeptly navigated the industry&#8217;s consolidation trends. By emphasizing integrated, analytics-driven solutions across its subsidiaries, IPG ensures its ability to deliver measurable results that appeal strongly to clients. Its commitment to digital innovation, transparency, and accountability resonates deeply with businesses increasingly prioritizing cost-effective strategies that maximize return on investment, positioning IPG favorably for sustained growth as the MarTech and PR sectors rebound.
Meanwhile, WPP plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPP#NYSE">WPP</a>), historically one of the most dominant forces in MarTech and PR globally, is undergoing a transformative restructuring aimed at maximizing the potential offered by industry consolidation. WPP's strategic divestitures of non-core assets and significant investments in AI-powered analytics and digital marketing capabilities illustrate a clear focus on emerging high-growth areas. This targeted strategy positions WPP as a rejuvenated market leader, poised to capitalize significantly on anticipated growth opportunities.
Beyond the strategic moves of individual companies, the broader consolidation trend reflects a structural shift in MarTech and PR. Companies are increasingly seeking integrated services that blend strategic insight, data analytics, creative execution, and measurable outcomes—all areas where consolidated holding companies excel. As economic stability returns, demand for sophisticated, integrated marketing and communication solutions is expected to surge, providing fertile ground for substantial revenue growth.
The ongoing consolidation in the MarTech and PR sectors has created optimal conditions for strong future performance. Holding companies such as Stagwell, Omnicom, IPG, and WPP are strategically positioned to benefit significantly from this environment, offering investors exposure to industries that stand ready to rebound and thrive in the coming economic cycle.

Equities

Opinion

Media

Trading Ideas

STGW

Stocks Poised To Benefit From Ongoing Consolidation In MarTech/PR Sectors

Global

Bessent Says We Will See If China Wants To Be A Responsible Partner

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated
Presentation at the Phoenix Best Science Series by HonorHealth Research Institute on June 27, 2025 in Scottsdale, Arizona
MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary TRBC product discovery and development platform technology.
The TRBC technology enabled the Company to construct T-cell engagers that not only target cancer antigens and CD3 activation of effector T cells, but also simultaneously reduce the immunosuppression in tumor microenvironment. Such immunosuppression plays a pivotal role in reducing effector T-cell infiltration and anti-tumor efficacy in solid tumors. The Company's two lead T-cell engagers target tissue factor and mesothelin, which are proven solid tumor antigens. These product candidates exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at dose levels that are well tolerated. Dr. Hing C. Wong, Founder and CEO of the Company, will present the details of these IND-enabling studies as an invited speaker for the Phoenix Best Science Series, hosted by HonorHealth Research Institute, located at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona, on June 27, 2025.

HCWB

HCW Biologics' Scientists Develops Second-Gen, Multi-Specific T-Cell Engagers Against Solid Tumors Using Proprietary TRBC Product Discovery And Development Platform Technology

WIIM

INMB

INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.

Mixed Martial Arts Group shares are trading higher after the company announced it partnered with Morphotech for a blockchain and AI crypto rewards platform.

Lotus Technology shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

CNXC

Concentrix shares are trading lower after the company reported a Q2 adjusted EPS miss and narrowed its FY25 adjusted EPS guidance.

AOUT

American Outdoor Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

CRMD

CorMedix shares are trading lower after the company announced an $85 million public offering.

RILY

B. Riley Financial shares are trading higher after the company sold its advisory services businesses, GlassRatner Advisory & Capital Group and B. Riley Farber Advisory, to funds managed by TorQuest Partners for $117.8 million.

Canaccord Genuity analyst Joseph Vafi maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Maintains Buy on Core Scientific, Maintains $17 Price Target

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk endorsed&nbsp;Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Satya Nadella&#8217;s&nbsp;perspective on&nbsp;the practical impact of AI, emphasizing its&nbsp;benefits to sectors like healthcare,&nbsp;education, and productivity.
What Happened: Musk, on X, supported Nadella&#8217;s views on AI&#8217;s progress, which were shared in a post by Nadella on June 25, 2025. Nadella, the CEO of&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), had stressed the importance of AI&#8217;s real-world outcomes over technical benchmarks at Y Combinator&#8217;s&nbsp;AI Startup School wherein Elon Musk commented &#8220;True&#8221;. Nadella stated that AI must produce results that are &#8220;socially useful.&#8221;
This shift in focus aligns with recent studies indicating AI&#8217;s&nbsp;potential to enhance GDP growth&nbsp;by addressing real-world challenges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">True <a href="https://t.co/iFlmTUzLwx">https://t.co/iFlmTUzLwx</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1938086636941939098?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;If we really are not creating social surplus, economic surplus, as measured by countries and communities, we just can&#8217;t consumer energy.&#8221; stated Nadella. 
&#8220;The real question in the next five years is we&#8217;ve got to produce enough products that are creating great value,&#8221; he added.
He also pointed out&nbsp;that the true measure of&nbsp;AI&#8217;s progress lies in&nbsp;its ability to improve real-world&nbsp;outcomes rather than just achieving&nbsp;technical benchmarks. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46131453/bitcoin-ethereum-rangebound-dogecoin-dips-amid-potential-july-tariff-deadline-extension-analyst-predicts-btcs-next-big-move-once-it-breaks-out-of-this-range" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Rangebound, Dogecoin Dips Amid Potential July Tariff Deadline Extension: Analyst Predicts BTC&#8217;s &#8216;Next Big Move&#8217; Once It Breaks Out Of This Range </a>
Why It Matters:&nbsp;Musk&#8217;s endorsement of Nadella&#8217;s view on AI&#8217;s real progress comes at a time when the tech industry is witnessing a shift towards focusing on&nbsp;the practical impact of AI.
CEO Satya Nadella believes that while AI is already <a href="https://www.benzinga.com/markets/tech/25/06/46111393/ai-is-already-speeding-up-discoveries-in-chemistry-and-physics-but-satya-nadella-says-the-real-breakthrough-will-come-when-we-add-quantum-computing-to-the-mix">driving major</a> scientific breakthroughs, its full transformative potential will be unlocked with the integration of quantum computing. Meanwhile, the growing role of AI in healthcare was highlighted, with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partnering with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to speed up drug discovery and development. 
However, Wall Street remains divided on AI's future—while some investors are optimistic about its disruptive potential, others express concerns over associated risks and the lack of transparency in how it is being managed.
On a year-to-date basis, ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) climbed 24.85% and 13.05%, respectively. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46127671/amazon-loses-top-ai-leader-in-high-stakes-talent-shuffle">Amazon Loses Top AI Leader In High-Stakes Talent Shuffle </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARKK

MSFT

NVDA

TSLA

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) will release earnings results for the first quarter after the <a href="https://www.benzinga.com/quote/STZ/earnings">closing bell on Tuesday, July 1.</a>
Analysts expect the company to report quarterly earnings at $3.29 per share, down from $3.57 per share in the year-ago period. Constellation Brands projects to report quarterly revenue at $2.56 billion, compared to $2.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, Barclays analyst Lauren Lieberman maintained a Constellation Brands rating of Overweight and lowered the price target from $207 to $202. JP Morgan analyst Andrea Teixeira maintained the stock with a Neutral rating and cut the price target from $194 to $170.
With the recent buzz around Constellation Brands, some investors may be eyeing potential gains from the company's dividends too. As of now, Constellation Brands offers an annual dividend yield of 2.53%, which is a quarterly dividend amount of $1.02 per share ($4.08 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $237,302 or around 1,471 shares. For a more modest $100 per month or $1,200 per year, you would need $47,428 or around 294 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.08 in this case). So, $6,000 / $4.08 = 1,471 ($500 per month), and $1,200 / $4.08 = 294 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
STZ Price Action: Shares of Constellation fell 0.1% to close at $161.32 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a></li>
</ul>
Photo: The Image Party/Shutterstock

Earnings

Long Ideas

Dividends

Markets

How To Earn $500 A Month From Constellation Brands Stock Ahead Of Q1 Earnings

Chinese electric vehicle manufacturer Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) stock traded lower on Friday after the company cut its delivery outlook for the <a href="https://www.benzinga.com/pressreleases/25/06/g46133821/li-auto-inc-updates-second-quarter-delivery-outlook" target="_blank" rel="noreferrer noopener">second quarter of 2025</a>.
This adjustment closely follows <a href="https://www.benzinga.com/markets/asia/25/06/46132552/telsla-model-y-rival-xiaomi-yu7-suv-receives-nearly-300000-orders-in-1-hour-in-china">Xiaomi&#8217;s successful YU7 SUV</a> launch, which aggressively undercut rivals like Tesla&#8217;s Model Y and intensified competition in the Chinese EV market.
Li Auto now anticipates delivering approximately 108,000 vehicles in the second quarter of 2025, which represents a 0.5% year-on-year decline.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/45881963/tesla-supplier-catl-hits-milestone-with-1-million-battery-packs-delivered-to-li-auto" rel="noreferrer noopener">Tesla Supplier CATL Hits Milestone With 1 Million Battery Packs Delivered To Li Auto</a>
This is a significant reduction from its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45667278/li-auto-q1-vehicle-deliveries-jump-15-continues-high-cash-burn" rel="noreferrer noopener">previous forecast</a> of 123,000-128,000 vehicles, which would have represented a 13.3%-17.9% year-on-year increase.
For context, Li Auto reported total vehicle deliveries of 108,581 units in the fiscal <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40595804/chinese-ev-maker-li-auto-q2-earnings-eps-beat-25-deliveries-growth-margin-struggles-and-more" rel="noreferrer noopener">second quarter of 2024</a>.
Li Auto attributes this adjustment to the temporary impact of an ongoing sales system upgrade, a strategic move intended to support its long-term growth.
It expressed conviction in completing its organizational upgrade before the launch of Li i8, enabling it to embrace the new product cycle effectively. The stock gained 53% in the last 12 months.
Li Auto <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45691082/tesla-rival-li-auto-will-release-2-new-suvs-this-year-ceo-li-xiang-hints-at-companys-first-sedan" rel="noreferrer noopener">plans to launch</a> two new SUVs in 2025 and may debut its first sedan if market conditions allow.
During its Q1 2025 earnings call, the company shared details about the Li i8, its first all-electric SUV designed for six passengers, and the smaller five-seat Li i6. Li Auto aims to release the i8 in July and the i6 in August.
The broader geopolitical landscape, particularly evolving U.S.-China trade relations, is influencing the semiconductor and EV sectors.
In the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45902627/us-listed-chinese-tech-and-ev-stocks-slide-as-trump-confirms-china-trade-deal" rel="noreferrer noopener">second week of June</a>, President&nbsp;Donald Trump confirmed a&nbsp;China trade deal&nbsp;after two days of negotiations in London, which sent the U.S.-listed Chinese stocks down. The U.S. plans to apply 55% tariffs on selected Chinese imports, while China will impose a 10% tariff rate on U.S. goods.
According to reports, U.S. and Chinese officials met in London for trade talks, which likely focused on rare earth minerals. Rare earth elements play significant roles in everything from smartphones to electric vehicles to fighter jets. The U.S. depends on China for ~70% of its imports of rare earth elements.
Furthermore, U.S. restrictions on China&#8217;s access to Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) technology have <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report" rel="noreferrer noopener">spurred Chinese automakers</a>, including Li Auto, to accelerate efforts to replace foreign semiconductors with domestic alternatives in their vehicles by 2027. At least two Chinese brands are reportedly aiming for mass production of cars using 100% domestic chips by 2026.
Price Action: LI stock is trading lower by 3.36% to $27.07 premarket at&nbsp;last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46116924/cyngn-stock-soars-135-after-partnering-with-nvidia-to-showcase-autonomous-industrial-vehicles" target="_blank" rel="noreferrer noopener">Autonomous Vehicle Solutions Provider Cyngn Stock Soars After Partnering With Nvidia &#8211; Here&#8217;s Why (UPDATED)</a></li>
</ul>
Photo by Robert Way via Shutterstock

Guidance

Movers

Tech

China's Li Auto Cuts Outlook As Xiaomi Challenges EV Giants

FOXO

FOXO Technologies Designates Series E Preferred Stock With Dual Dividends As Acquisition Currency And Capital Raise Tool

Nike shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

Press Releases

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Legal

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

Financing

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

Comments

Liquidia

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL